Heron Therapeutics Stock News

Mackay Shields LLC trimmed its position in Heron Therapeutics Inc (NASDAQ:HRTX) by 19.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Excha

Heron Therapeutics Inc (NASDAQ:HRTX) – Stock analysts at Cantor Fitzgerald reduced their FY2020 earnings per share (EPS) estimates for shares of Heron Therapeutics in a research report issued on Thu

Charles Schwab Investment Management Inc. lifted its stake in Heron Therapeutics Inc (NASDAQ:HRTX) by 15.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exc

Shares of Heron Therapeutics Inc (NASDAQ:HRTX) traded down 7.1% during mid-day trading on Thursday . The stock traded as low as $17.06 and last traded at $17.32, 1,154,089 shares were traded during tr

Heron Therapeutics Inc (NASDAQ:HRTX) – Investment analysts at Jefferies Financial Group issued their Q1 2020 earnings estimates for shares of Heron Therapeutics in a report issued on Monday, March 2

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Heron Therapeutics (NASDAQ:HRTX) had its price objective decreased by analysts at Needham & Company LLC from $48.00 to $44.00 in a research report issued to clients and investors on Monday, BenzingaRa

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on EyePoint Pharmaceuticals (EYPT), uniQure (QURE) and Heron

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on EyePoint Pharmaceuticals ( EYPT – Research Report ), uniQure ( QURE – Research Report ) and Heron T

Heron Therapeutics (NASDAQ:HRTX)‘s stock had its “buy” rating restated by stock analysts at Stifel Nicolaus in a note issued to investors on Monday, TipRanks reports. They currently have a $29.0

After Cowen & Co. and Cantor Fitzgerald gave Heron Therapeutics (NASDAQ: HRTX) a Buy rating last month, the company received another Buy, this time

After Cowen & Co. and Cantor Fitzgerald gave Heron Therapeutics (NASDAQ: HRTX) a Buy rating last month, the company received

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -12.07% and 0.81%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO (AP) _ Heron Therapeutics Inc. (HRTX) on Monday reported a loss of $57.9 million in its fourth quarter. The San Diego-based company said it had a loss of 65 cents per share. The results miss